Alpha-1 Antitrypsin Deficiency Beyond COPD and Emphysema: A Narrative Review
Medical Sciences · 22.02.2026 · 14 (1) · 106
DOI: 10.3390/medsci14010106 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Sciences, online erschienen am 22.02.2026. Verfasst von Lucia Pastoressa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41124 Modena, Italy. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin Deficiency, Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Asthma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: COPD
Abstract (Originalsprache)
Background/Objectives: Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder classically associated with emphysema and COPD. However, emerging evidence indicates that its clinical spectrum extends to airway-predominant diseases such as bronchiectasis and asthma, where protease–antiprotease imbalance and neutrophilic inflammation may drive tissue injury. This narrative review aims to synthesize current evidence on the relationship between AATD and airway diseases beyond emphysema, focusing on epidemiological patterns, underlying mechanisms, diagnostic strategies, and therapeutic implications.
Methods
A narrative synthesis of the literature was performed, integrating data from registries, with observational and translational studies addressing the prevalence, pathobiology, and therapeutic implications of AATD in bronchiectasis, asthma, and severe asthma. Epidemiologic and mechanistic insights were analyzed to identify overlapping pathways and evidence gaps.
Results
Evidence supports a non-negligible prevalence of bronchiectasis and asthma among AATD individuals, particularly in severe or heterozygous genotypes. Neutrophil elastase overactivity, impaired mucociliary clearance, and chronic neutrophilic inflammation emerge as shared mechanisms promoting bronchial remodeling and airflow limitation. In asthma, AATD appears linked to T2-low, steroid-resistant phenotypes and persistent obstruction, whereas in severe asthma cohorts, up to 20% may carry non-PiMM SERPINA 1 variants. No randomized trials have evaluated augmentation therapy and standardized screening algorithms are lacking.
Conclusions
AATD represents a systemic disorder with clinically relevant airway manifestations beyond COPD and emphysema. Targeted testing should be considered in patients with idiopathic bronchiectasis or severe asthma. Future genotype-stratified, prospective studies are required to clarify causality, define biomarkers of disease activity, and evaluate the potential role of anti-protease-based therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41124 Modena, Italy.
- Respiratory Diseases Unit, University Hospital of Modena-Policlinico, 41124 Modena, Italy.
- Center for Rare Lung Diseases, University Hospital of Modena-Policlinico, 41124 Modena, Italy.
ORCID-Profile: Vanessa Pivetti, Enrico Clini, Stefania Cerri
Zitieren
APA
Pastoressa, L., Pivetti, V., Valente, M., Beghè, B., Clini, E., Tonelli, R., & Cerri, S. (2026). Alpha-1 Antitrypsin Deficiency Beyond COPD and Emphysema: A Narrative Review. Medical Sciences, 14(1), 106. https://doi.org/10.3390/medsci14010106
Vancouver
Pastoressa L, Pivetti V, Valente M, Beghè B, Clini E, Tonelli R, et al. Alpha-1 Antitrypsin Deficiency Beyond COPD and Emphysema: A Narrative Review. Medical Sciences. 2026;14(1):106. doi:10.3390/medsci14010106
BibTeX
@article{Pastoressa2026,
author = {Pastoressa, Lucia and Pivetti, Vanessa and Valente, Marialuisa and Beghè, Bianca and Clini, Enrico and Tonelli, Roberto and Cerri, Stefania},
title = {Alpha-1 Antitrypsin Deficiency Beyond COPD and Emphysema: A Narrative Review},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {1},
pages = {106},
doi = {10.3390/medsci14010106}
}
EUVIMED